Maravai LifeSciences Experiences Unusual Options Activity

On January 9th, 2025, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) witnessed a significant spike in options trading volume. Investors acquired 1,002 put options, marking an astounding increase of approximately 1,791% compared to the usual average of 53 put options traded daily.

Insider Transactions at Maravai LifeSciences

In related news, insider Carl Hull made a notable purchase on November 11th, acquiring 175,000 shares of Maravai LifeSciences. The shares were bought at an average price of $5.64 each, resulting in a transaction worth about $987,000. This acquisition raised Hull's total ownership to 175,000 shares, equating to a total value of $987,000. The details of this transaction were disclosed in a filing with the SEC, which can be reviewed on their official website. Currently, insiders hold around 0.63% of the company's stock.

Hedge Fund Activities Regarding Maravai LifeSciences

Recently, several hedge funds have adjusted their stakes in Maravai LifeSciences. In the second quarter, Bank of New York Mellon Corp amplified its holdings by 30.1%, now owning 506,413 shares valued at approximately $3,626,000 after acquiring an additional 117,120 shares. Zurcher Kantonalbank also increased its position by 32.3%, accumulating 25,450 shares now valued at $182,000 following a purchase of 6,212 additional shares. Principal Financial Group Inc. raised its holdings by a striking 62.4%, holding 666,187 shares worth $4,770,000 after obtaining 255,990 more shares. Rhumbline Advisers increased their stake by 30.4%, ending up with 171,489 shares valued at $1,228,000. Additionally, Choreo LLC has recently acquired a new position in Maravai LifeSciences valued at around $467,000. Institutional and hedge fund investors collectively own approximately 50.25% of the company's shares.

Maravai LifeSciences Stock Performance

On January 10th, 2025, shares of Maravai LifeSciences opened at $6.13. The company has a market capitalization of $1.55 billion and reported a 12-month stock low of $4.28 and a high of $11.56. The stock's 50-day simple moving average stands at $5.73, while the 200-day average is $7.43. Maravai LifeSciences has a current ratio of 10.74, a quick ratio of 9.94, and a debt-to-equity ratio of 0.89.

Recent Analyst Ratings for Maravai LifeSciences

Several brokerages have recently revised their ratings for Maravai LifeSciences. In a report dated November 8th, Robert W. Baird reduced their price target from $10.00 to $9.00, maintaining an “outperform” rating. Wolfe Research initiated coverage on the stock on November 14th, giving it a “peer perform” rating. Also, William Blair has reasserted a “market perform” rating. On December 5th, Goldman Sachs downgraded their rating from “neutral” to “sell,” lowering the price target from $7.00 to $4.25. Guggenheim has begun coverage on the stock as well, providing it with a “neutral” rating. In total, one analyst has assigned a sell rating, five have given hold ratings, and five have issued buy ratings for the stock. According to MarketBeat, the average rating for Maravai LifeSciences is “Hold” with an average target price of $10.28.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc. is a prominent life sciences company that provides essential products for the development of drug therapies, diagnostics, and innovative vaccines. They support global research into human diseases, offering key products that facilitate various biopharmaceutical development stages. Their product range includes nucleic acids for therapeutic and diagnostic purposes, and antibody-based products to detect impurities in biopharmaceutical production, along with products for protein expression analysis in tissue samples from multiple species.

options, trading, investors